knowledge -WSS

knowledge

author：explore 2025-09-28 23:11:45 - browse：17127

Geoff Martha, CEO of Medtronic Courtesy Medtronic

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Why Novartis is going to walk from its acquisition of MorphoSys

explore

WSS

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Primary care physicians play key roles in Alzheimer's management

Decaf coffee targeted by food safety group under obscure FDA rule

Readout LOUD: Venture capital, Gilead, and more M&A

Merck drug for rare lung condition set for approval in U.S.

Merck drug for rare lung condition set for approval in U.S.

leisure time

knowledge

leisure time

In Memoriam: Notable people who died in 2023

AstraZeneca stays mum on Medicare drug pricing negotiations

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Supreme Court mifepristone arguments center on docs' right to sue

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Global cancer cases to surge 77% by 2050, WHO report says

Supreme Court strikes down use of affirmative action

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

DIEP, the 'gold standard' of breast reconstruction, is under threat

340B reform proposal comes out of Senate working group

entertainment

Why Novartis is going to walk from its acquisition of MorphoSys

Merck drug for rare lung condition set for approval in U.S.

Scientists boost immune system in aging mice by making it youthful

AI gets buy

There's no autism epidemic. It's an autism diagnosis epidemic

What’s missing from the debate over nursing home staff minimums

explore

explore

explore

hotspot